-
Thiothixene: A PK-to-Efferocytosis Research Guide
2026-09-08
Thiothixene is a typical antipsychotic agent with a distinctive research profile spanning dopamine signaling pathway modulation and macrophage efferocytosis. This guide connects mechanism, pharmacokinetic evidence, and assay design so researchers can distinguish clinically informed exposure questions from in vitro immune-cell workflows.
-
WY-14643 (Pirinixic Acid): PPARα Research Guide
2026-09-08
WY-14643, also called Pirinixic Acid, is a selective PPARα research agonist with a reported human PPARα IC50 of 10.11 µM. It supports mechanistic studies of lipid metabolism regulation, endothelial inflammation, and insulin sensitivity enhancement, but product-level findings should not be treated as clinical efficacy.
-
iRhom2 in Olfaction: Receptor Adaptation
2026-09-07
Azzopardi and colleagues identify iRhom2 as a distinctive component of olfactory sensory neurons and connect its expression to odor-dependent regulation of olfactory receptor and activity-gene programs. Their combination of knockout analysis, transcriptomics, spatial validation, and receptor stimulation suggests an iRhom2/ADAM17-linked feedback mechanism, while also defining important limits for causal interpretation.
-
Lactate Workflows for Metabolic–Immune Research
2026-09-07
Use L-lactate as both a quantitative metabolic readout and a controlled signaling input in glycolysis, hypoxia, mitochondrial, and tumor–immune experiments. This workflow connects careful compartment-specific sampling with mechanistic testing of the NAT1–ENO1–lactate–PD-L1 axis.
-
Deracoxib–Doxorubicin in Canine Mammary Cells
2026-09-05
The reference study examined whether deracoxib could reduce doxorubicin-associated injury in cultured normal canine mammary epithelial cells. Its central contribution is the integrated assessment of viability, apoptosis, and nitric oxide production, showing that a COX-2 inhibitor may protect nonmalignant mammary cells while altering the cellular response to chemotherapy.
-
CXCL1–CXCR2 Signaling in Pancreatic Cancer Pain
2026-09-04
A study in Brain, Behavior, and Immunity identifies an NTS-centered CXCL1–CXCR2–microglia pathway that contributes to pancreatic cancer-induced pain. Its combination of transcriptomics, neural activity measurements, microglial morphology, behavioral testing, and region-specific pharmacology provides a mechanistic framework for studying central visceral cancer pain.
-
Caffeine Workflows for Translational Cell Research
2026-09-04
Caffeine supports reproducible cancer cell line inhibition studies, combination testing with valproic acid, and energy metabolism modulation in diet-induced obesity mouse models. This guide turns its solubility profile and approximately 2 mM in vitro benchmark into practical preparation, dosing, controls, and troubleshooting decisions.
-
Angiotensin I Workflows for RAS Research
2026-09-03
Use Angiotensin I as a controllable substrate to dissect renin–angiotensin system research, quantify ACE-dependent conversion, and improve antihypertensive drug screening. This workflow also clarifies when a decapeptide challenge is informative in cardiovascular, neuroendocrine, and emerging peptide–receptor binding assays.
-
How Near-Death Tumor Cells Become Metastatic
2026-09-03
Conod, Silvano, and Ruiz i Altaba identify a mechanism by which tumor cells that survive impending death acquire stable prometastatic properties. Their study defines PAMEs, links their formation to ER stress and nuclear reprogramming, and shows that a cytokine-driven interaction with neighboring cells creates a broader prometastatic ecosystem.
-
LRG1 and Neutrophil Mitochondria in Bladder Cancer
2026-09-02
The Advanced Science study identifies an LRG1–ANXA2–neutrophil pathway that links tumor-derived LRG1 to mitochondrial stress, NET release, vascular destabilization, and treatment resistance in bladder cancer. Its integrated single-cell, molecular, and in vivo strategy suggests that disrupting NETosis may normalize tumor vessels and improve responses to cisplatin and anti-PD-1 therapy.
-
Non-Betalain DODA and Stress Adaptation in Pansy
2026-09-02
A 2025 study shows that VwDODA, a non-betalain DODA homolog from pansy, has a stress-related metabolic role rather than a canonical pigment-producing function. Through biochemical, heterologous-expression, and promoter analyses, the authors link VwDODA to salt tolerance, pathogen resistance, antioxidant defense, ABA signaling, and VwMYB20-associated regulation.
-
PPT (Propyl Pyrazole Triol): ERα Research Guide
2026-09-01
PPT (Propyl Pyrazole Triol) is a potent, selective ERα agonist for separating estrogen receptor alpha signaling from ERβ activity in research models. B6735 combines strong reported subtype preference with defined solvent, storage, gene-expression, and uterotrophic assay information.
-
BCL6–ESM1 Axis in Hepatocellular Carcinoma Immunity
2026-09-01
The reference study identifies cancer-cell BCL6 as an immune-evasion regulator in hepatocellular carcinoma, linking reduced inflammatory signaling and increased ESM1 to impaired tumor-infiltrating CD4+ T-cell recruitment and cytotoxicity. Its findings shift attention beyond CD8+ T-cell quantity toward CD4+ T-cell function and suggest a paracrine mechanism that may influence future combination immunotherapy research.
-
Diminazene Aceturate Research Workflows
2026-08-31
Diminazene Aceturate supports two distinct research tracks: trypanosome parasite screening and mechanistic ACE2 activation studies. This workflow-focused guide covers stock preparation, assay design, cross-domain interpretation, and troubleshooting without treating antiparasitic activity as proof of mitochondrial protection.
-
Hexa His tag peptide for cleaner IP workflows
2026-08-31
The Hexa His tag peptide enables antibody-compatible, competitive elution of His-tagged proteins while minimizing immunoglobulin heavy- and light-chain carryover. This practical guide covers assay setup, quantitative starting conditions, interaction studies, troubleshooting, and how emerging sequence-based binding models may inform future validation strategies.